Remove 2025 Remove FDA Remove Immunization
article thumbnail

Meeting Preview: McKesson ideaShare 2025

Drug Topics

McKesson ideaShare 2025 will take place this week in Nashville, Tennessee, and will include educational sessions, keynote sessions, networking events, and hands-on activities. This year’s conference is taking place from July 10 to 13 in Nashville, Tennessee. There is a total of 11 continuing education credits for the 3-day conference.

article thumbnail

FDA Approves Nitisinone for Treatment of Alkaptonuria

Drug Topics

The FDA approved nitisinone (Harliku) for the reduction of urine homogentisic acid (HGA) in patients with alkaptonuria (AKU). The FDA approved nitisinone (Harliku) for the reduction of urine homogentisic acid (HGA) in patients with alkaptonuria (AKU). The medication is expected to launch in July 2025. REFERENCES 1.

FDA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Insulin Aspart-Xjhz as First Interchangeable Biosimilar to NovoLog

Drug Topics

The FDA approved insulin aspart-xjhz (Kirsty) 100 units/mL as the first and only interchangeable biosimilar to insulin aspart (NovoLog). 1 The FDA approves Kirsty, an interchangeable biosimilar insulin, enhancing diabetes treatment options and accessibility for patients. July 15, 2025. Accessed July 21, 2025.

FDA
article thumbnail

How the Rise in US Pharmacy Deserts Impacts Patients’ Health

Drug Topics

They're providing clinical advice, testing, immunizations, and many other necessary services to maintain good health. April 28, 2025. Pharmacy closures have become commonplace within the industry as of late, with thousands of shutdowns since 2010 and a trend that’s showing significantly more pharmacy closures than openings.

article thumbnail

GLP-1s Effective as Adjunctive Therapy in Patients with T1D, Obesity | ADA 2025

Drug Topics

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were safe and effective as adjunctive therapies for patients with type 1 diabetes (T1D) and overweight or obesity, according to an abstract presented at the American Diabetes Association 85th Scientific Sessions, held in Chicago, Illinois, from June 20-23, 2025.

article thumbnail

Q&A: Pharmacist Highlights Challenges in Vaccine Information Navigation Amid Changing Recommendations

Drug Topics

She highlighted the challenges of maintaining accurate, transparent vaccine guidance, focusing on the importance of trusted health care providers helping patients understand immunization strategies. This schedule also helped dictate insurance coverage of those recommended vaccines.

article thumbnail

FDA Approves Widaplik for Treatment of Hypertension

Drug Topics

The FDA approved telmisartan, amlodipine and indapamide (Widaplik) for the treatment of hypertension in adult patients, George Medicines said in a release. The FDA approved telmisartan, amlodipine and indapamide (Widaplik) for the treatment of hypertension in adult patients, George Medicines said in a release. June 9, 2025.

FDA